Loading quotes...

Forecast

The analysts' average price target is €9.99 (+169.27%). The median is €9.08 (+144.74%).

Buy
  11
Hold
  3
Sell
  7

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • MannKind achieves positive phase‑1b results for inhaled nintedanib in IPF

    MannKind reports positive topline results from the randomized, double‑blind phase‑1b study INFLO‑1 of inhaled nintedanib as a dry powder in patients with idiopathic pulmonary fibrosis (IPF). The 27‑patient study showed no serious adverse events, no drug‑related gastrointestinal side effects, no bronchospasms and no discontinuations or dose reductions; cough was mostly mild and transient. Overall, IPF patients received about 450 inhalations; combined with phase‑1a, 48 people were treated, 18 of them with IPF. The global phase‑2 study INFLO‑2 to further evaluate nintedanib DPI is currently recruiting and is expected to enroll around 210 participants. » More on de.investing.com


  • Wells Fargo upgrades MannKind after pediatric Afrezza approval, calls commercial potential a “show‑me story”

    Wells Fargo raised its price target on MannKind to $11 and kept an Overweight rating, citing FDA approval of Afrezza for patients aged 6 and older and supportive INHALE‑1 data. The approval expands Afrezza’s market to pediatric patients and caregivers. MannKind also highlighted potential near‑term upside from up to $35 million in development milestones, a 10% royalty on net sales and its role as sole manufacturer of Tyvaso DPI. » More on finance.yahoo.com


  • MannKind completes patient recruitment for INFLO‑1 and starts global phase‑2 for Nintedanib DPI

    MannKind has completed randomization of patients in the phase‑1b trial INFLO‑1 and has enrolled the first patient in the global phase‑2 trial INFLO‑2 for Nintedanib DPI. INFLO‑1 evaluates safety, tolerability and pharmacokinetics; results are expected in Q3 2026. INFLO‑2 aims to recruit about 210 participants at roughly 85 sites in a randomized, double‑blind 1:1:1 design over 12 weeks (with a 24‑week open extension) for dose finding and safety assessment. » More on de.investing.com


  • MannKind: shareholders re-elect nine directors, approve compensation and auditor

    At the annual general meeting, shareholders re-elected all nine nominated MannKind directors and voted in an advisory capacity to approve the board’s compensation. Deloitte & Touche was confirmed as the independent auditor for the fiscal year ending December 31, 2026. In quarterly results, MannKind reported a 15% revenue rise to $90 million, mainly driven by FUROSCIX following the acquisition of scPharmaceuticals, but missed the EPS forecast of -$0.01 with a non-GAAP net loss of $0.02 per share. » More on de.investing.com


  • MannKind records Q1 revenue up 15% and sees three near-term regulatory catalysts

    MannKind reported Q1 2026 revenue of $90 million (up 15% year-over-year), driven by the integration of FUROSCIX; the adjusted non-GAAP result showed a loss of $6.9 million. Management emphasizes strategic diversification away from a one-product model and identifies three imminent value drivers: Afrezza Pediatrics (PDUFA May 29), the FUROSCIX ReadyFlow autoinjector (PDUFA July 26), and nintedanib DPI with topline data in Q3 and the start of Phase 2 recruitment. The partnership with United Therapeutics for Ralinepag DPI was also expanded, including an upfront payment and milestones, and the revenue outlook for FUROSCIX in 2026 remains $110–120 million. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, MannKind Co. has already paid €7.52 in dividends. The last payout was in September 2022.

Financials

In the last quarter, MannKind Co. had revenue of €89.94m and net profit of -€20.5m
(EUR) September 2026
YoY
Revenue 89.94m 28.51%
Gross profit 69.18m 31.09%
Net profit -20.5m 401.33%
EBITDA -4.73m 131.10%

Fundamentals

Metric Value
Market capitalization
€1.2bn
Number of shares
321.64m
52-week high/low
€5.91 - €2.02
Dividends No
Beta
1.09
P/E ratio
-17.52
PEG ratio
0.17
P/B ratio
-35.44
P/S ratio
3.21

Company profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Name
MannKind Co.
CEO
Michael E. Castagna
Headquarters Danbury, ca
USA
Website
Sector
Materials
Industry
Chemicals
IPO
28/07/2004
Employees 592

Ticker symbols

Exchange Symbol
NASDAQ
MNKD
Frankfurt
NNFN.F
DĂĽsseldorf
NNFN.DU
SIX
NNFN.SW
MĂĽnchen
NNFN.MU
🍪

Parqet  uses cookies. Learn more